This week, the FDA grants approval on two treatments: oral omadacycline for community-acquired bacterial pneumonia and Trikafta for children aged 6 to 11 with cystic fibrosis; more than 70% of COVID-19 patients experience at least one persistent symptom; many patients self-identify the need for pulmonary rehab following COVID-19 hospitalization; and children who had mild or asymptomatic COVID-19 do not need to be cleared for sports, according to the AAP.

Read the full coverage here:

FDA approves omadacycline oral regimen for community-acquired bacterial pneumonia

FDA approves Trikafta for children aged 6 to 11 with cystic fibrosis

More than 70% of COVID-19 patients experience at least one persistent symptom

Many patients self-identify need for pulmonary rehab following COVID-19 hospitalization

AAP: Children who had mild or asymptomatic COVID-19 do not need to be cleared for sports